While the biotechnology industry is constantly evolving, intellectual property remains a fundamental pillar of a biotech company’s developing framework. Innovation is in “Allele’s DNA,” and securing patent-worthy discoveries and technologies plays a big part in how we contribute to science and society.
We recently received a Notice of Allowance from the U.S. Patent and Trademark Office on 2/21/25 for our patent “Induction of Pancreatic Beta Cells by Stem Cell Differentiation with RNA” (U.S. Patent pending). This patent is particularly significant to Allele Biotech’s operations moving forward. Using an internally developed high-efficiency methodology, we produce high-purity beta islets for treating diabetes. Derived from either personalized or allogeneic induced pluripotent stem cells (iPSCs), these islets are a leading asset in our internal product pipeline.
Additionally, we have secured important new patents covering multiple stem cell differentiation processes, marking major milestones in our mission to revolutionize stem cell therapy. These include:
- Australian Patent No. 2017363145 (granted May 30, 2024) – Induction of pancreatic beta cells by stem cell differentiation with RNA
- Australian Patent No. 2017363142 (granted September 12, 2024) – Induction of hepatocytes by stem cell differentiation with RNA
- Taiwanese Patent Application (number pending) – Induction of hepatocytes by stem cell differentiation with RNA
- U.S. Patent No. US 12,104,171B2 – Induction of neural progenitor cells, oligodendrocyte progenitor cells, and oligodendrocytes by stem cell differentiation using landmark transcription factors
- Hong Kong Patent No. HK40020599 (granted January 28, 2025) – Induction of neural progenitor cells, oligodendrocyte progenitor cells, and oligodendrocytes by stem cell differentiation
These new patents add to our ever-growing portfolio, which also includes our fluorescent protein patents, most notably mNeonGreen, a key factor in major litigation settlements.
Our new patents:
- Australian Patent No. 2017363145 (May 30, 2024) – Induction of pancreatic beta cells by stem cell differentiation with RNA
- Australian Patent No. 2017363142 (September 12, 2024) – Induction of hepatocytes by stem cell differentiation with RNA
- U.S. Patent No. US 12,104,171B2 – Induction of neural progenitor cells, oligodendrocyte progenitor cells, and oligodendrocytes by stem cell differentiation using landmark transcription factors
- Hong Kong Patent No. HK40020599 (January 28, 2025) – Induction of neural progenitor cells, oligodendrocyte progenitor cells, and oligodendrocytes by stem cell differentiation
- Taiwanese Patent Application (number pending) – Induction of hepatocytes by stem cell differentiation with RNA
For the latest updates, subscribe to our newsletter and follow us on LinkedIn and our other social platforms.